Management of stones in the biliary tree
Stones in the biliary tree may coexist with gall-bladder stones, may be found only in the common duct (in the absence of gall-bladder stones) or, more rarely, may be present in the intrahepatic biliary tree -as in the Caroli syndrome.1 One of the most frequent causes of choledocholithiasis, however, is the retained common duct stone which has been left behind inadvertently after elective or emergency cholecystectomy. Despite the routine use of intraoperative cholangiography, exploration of the common duct (where indicated) at the time of cholecystectomy and even, on occasions, the use of fibre optic choledochoscopy, there is still a 1-4% incidence of retained common duct stones after cholecystectomy.2 When stones are discovered in the biliary tree, there are several therapeutic options -including, in selected patients, the use of oral chenodeoxycholic (CDCA) or ursodeoxycholic (UDCA) acid, the gall-stone dissolving agents which are more commonly used in the treatment of cholesterol-rich stones in the gall bladder. 3 Elsewhere in this issue Dr Gianfranco Salvioli and his colleagues from Modena in Italy describe the results of a random allocation, double masked trial in 28 patients with uncomplicated biliary stones, half of whom were treated with 12 mg UDCA/kg/day in three divided doses, while the other half received placebo. Seventeen of these patients had stones in the gall bladder while four had a radiologically normal gall bladder with stones only in the biliary tree. Although the end point of the study was intended to be 24 months, only four of the 28 patients actually completed the two year trial -either because the stones had disappeared completely before that time, or because the patients developed biliary colic, pain or cholangitis, underwent surgery or simply 'dropped out'. None of the 14 patients given placebo showed evidence of gall-stone dissolution, but seven of the 14 UDCA-treated patients showed complete disappearance of the stones, as judged by normal intravenous cholangiograms, after six, 12, or 18 months' treatment -while one showed partial gall stone dissolution (defined as at least a 25% reduction in stone diameter or the disappearance of one or more stones).
If one arbitrarily classifies 'drop-outs' as treatment failures, then the complication rate, whether because of the stones or of the treatment, was higher in the placebo treated patients (12 out of 14) than in the UDCA-treated group (six out of 14). The reason for the 'drop-outs' in three of the 14 patients given UDCA is not stated. These patients may simply have defaulted from treatment because they lacked motivation or they may have become disenchanted with it for good reason -because of complications for example. Of the three other UDCA-treated patients who stopped, one underwent surgery for obstructive jaundice after three months, one developed colic, and one pain (the distinction between biliary colic and abdominal pain or discomfort, was not defined).
Given the choice between ursodeoxycholic acid and chenodeoxycholic acid as oral, gall-stone dissolving treatments for either gall bladder or biliary tree stones, the evidence at present favours UDCA. It appears to be a more 'benign' treatment which causes no appreciable diarrhoea, or hepatoxicity. The only possible side-effect of UDCA recognised to date is impaired calcium solubility during treatment,4 which might render further dissolution therapy ineffective.5 This phenomenon also occurs spontaneously and during CDCA treatment, but we do not yet know if it develops more frequently during ursotherapy. The Modena study was not designed to compare oral CDCA and UDCA in the treatment of stones in the biliary tree, but the Salvioli et al results support the idea that UDCA is indeed non-toxic. In fact, they found significant reductions in serum alkaline phosphatase and transaminase concentrations during treatment. The reduction in fasting serum triglycerides noted in the Modena study, however, is a controversial finding during ursotherapy. It was first reported during chenotherapy by Bell et 4 g/100 ml but although they gave results for relative molar composition of the three major biliary lipids, they did not indicate the absolute concentrations in their fasting duodenal bile samples).
The results of Salvioli et al are also unusual in that before UDCA treatment began, the lithogenic indices in fasting duodenal bile were exceptionally high. Normally there is a diurnal variation in bile lipid composition 6 17 and it is believed that the sequestration of an appreciable proportion of the bile acid pool in the gall bladder during fasting results in a physiological interruption of the enterohepatic circulation, with a secondary increase in biliary cholesterol saturation. Bile is therefore at its most supersaturated after an overnight fast. After cholecystectomy, however, the pool can no longer be seqestered in the gall bladder and even though removal of the gall bladder may result in a slightly smaller bile acid pool,18 because that pool is cycling constantly, it tends to lower biliary cholesterol saturation and to render the bile unsaturated in cholesterol. The concept that common duct stones may pass through the ampulla of Vater spontaneously is, of course, well recognised. In a much quoted study from Argentina, Acosta and Ledesma23 found gall stones in the stools from 34 out of 36 patients who presented with acute pancreatitis associated with gall stones. Sieving stools, however, is never a popular occupation -even for gastroenterologists -and this was not done in the Italian study. The fact that serial radiographs taken at six month intervals, however, showed a sequential reduction in gall stone size in five of the eight patients who later showed partial, or complete stone disappearance suggests that the oral UDCA treatment did at least reduce stone size, which may have facilitated their subsequent passage through the sphincter of Oddi. policy in the treatment of radiolucent gall stones in the gall bladder and the biliary tree. Furthermore, at present we have too little information to comment usefully on the treatment of stones confined to the intrahepatic biliary tree. Let us restrict our further discussion, therefore, to patients with retained radiolucent common duct stones which have been detected after cholecystectomy. The treatment options in such a patient have been reviewed several time before35 36 and these are summarised schematically in the form of a flow diagram in Fig. 1 . Once the diagnosis of radiolucent common duct stones has been made, irrespective of whether or not the common duct has been explored and a t-tube inserted at the time of the elective cholecystectomy, the option of (i) a second operation, (ii) endoscopic sphincterotomy with or without the use of mechanical extraction techniques, or even endoscopic placement of naso-biliary catheters for direct infusion of gall-stone dissolving agents, or (iii) an expectant approach -treating symptoms if and when they arisemay be considered. (iv) If oral dissolution therapy such as that described by Salvioli et al is to be considered, the common duct gall stones should be radiolucent and it is helpful to confirm that the stones removed from the gall bladder during cholecystectomy are indeed cholesterol-rich. This assumes, of course, that (a) the stones present in the common duct originated in the gall bladder, (b) they are, therefore, of the same generation and composition as the gall-bladder stones, and (c) during their residence in the biliary tree, the stones have not become appreciably modified -for example, by the deposition of amorphous non-cholesterol material which would render them unsuitable for dissolution therapy (Fig. 2) .
Surgery -the second laparotomy
Despite the fact that the morbidity and mortality for a second operation on the biliary tree is appreciably greater than that of an elective cholecystectomy and despite the fact that a second operation is often technically more difficult -many still feel that a direct surgical approach is the treatment of choice for common duct stones.
Edoscopic sphincterotomy
In experienced hands, endoscopic sphincterotomy carries only a small risk -comparable with, or smaller than surgical exploration of the duct. Sphincterotomy may be contra-indicated for larger stones measuring more than 12 mm in diameter, which are likely to be impacted in the biliary tree. The cost, benefit and risks of endoscopic sphincterotomy, with or without mechanical extraction using such devices as FogartZ balloons or Dormia baskets, has also been reviewed extensively37-3 and need not be considered further here. The endoscopic placement of naso-biliary catheters and even the use of sonic disintegration of stones by endoscopically guided sonic probes are interesting new approaches which are presently under evaluation.
Conservative approach
The natural history of untreated choledocholithiasis has been poorly studied -as indeed has the natural history of untreated stones in the gall bladder. The fate of untreated gall-bladder stones has been the subject of intense recent interest as a result of an article by Gracie and Ransohoff, 40 three associated editorials4143 and related correspondence in the medical press,44-47 suggesting that 'innocent' or silent gall stones are not a myth.
While this may be true early in the evolution of gall-stone disease when the stones are confined to the gall bladder, it is widely believed that the frequency of complications -such as biliary colic, obstructive jaundice, and gall-stone associated pancreatitis -are considerably greater in patients with choledocholithiasis, than in those with stones in the gall bladder. Indeed, it is for this reason that many investigators with a special interest in the medical dissolution of gall stones have abandoned attempts to dissolve common duct stones with cheno-or urso-deoxycholic acids. 
Conclusions
The study by Salvioli and his colleagues is important in that it establishes the feasibility of oral dissolution therapy for stones in the biliary tree. In a reasonable number of patients the authors have confirmed that bile acid treatment can lead to dissolution/disintegration/disappearance of common duct and biliary tree stones.49 50 The inclusion of a placebo group and the use of a double blind study design are valuable, not so much for establishing the efficacy of treatment as a means of ridding the biliary tree of stones, but more for the collateral information which such a study provides -the effect of UDCA on symptoms and compliance, withdrawals and drop-outs and on serum lipids and liver function tests. Nevertheless, 6-24 months ursotherapy is expensive and in the hierarchy of treatment options, many would consider other forms of management preferable.
In patients who have accessible small or medium sized common duct stones of any type (radiolucent or radio-opaque; cholesterol-rich, calciumrich or pigment-rich), endoscopic sphincterotomy ± mechanical extraction is probably the treatment of choice. It is quick (often instantaneous or, at most, requiring one to two weeks) and, in experienced hands highly effective, although it does carry a small risk of morbidity and mortality. Infusion/dissolution therapy through t-tubes or down endoscopically placed nasobiliary catheters60 62 also has a place in the treatment of retained radiolucent cholesterol-rich common duct stones. It too is relatively quick (one to four weeks) and reasonably effective, but can be tiring for the patient and side-effects limit its acceptability. In specialist units, mechanical extraction of retained common duct stones through mature t-tube tracts (the Burhenne technique58), may sometimes be helpful in avoiding surgery -particularly in the older age groups who tolerate second operations on the biliary tree rather poorly.
Perhaps the time has come, therefore, for surgeons, endoscopists, radiologists, and physicians to pool their resources and to plan a prospective random-allocation trial in an attempt to find the 'best buy' for the management of patients with choledocholithiasis. 
